Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.57 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | PPP5C | P53041 | 2/20 | 0.41 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.41 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3331942 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL3832732 | 1.00 | DPP4 (0.57) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL14123972 | 0.95 | HTT (0.58) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL6202288 | 0.95 | HTT (0.58) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL24322604 | 0.95 | LMNA (0.51) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL18390884 | 0.95 | LMNA (0.51) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL16134880 | 0.91 | HTT (0.50) | DPP4DPP8DPP9HTTLMNA | |
| SCHEMBL11439644 | 0.91 | DPP4 (0.66) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL21552116 | 0.91 | DPP4 (0.66) | DPP4DPP8DPP9FAPDPP7 | |
| SCHEMBL488953 | 0.85 | DPP4 (0.64) | DPP4DPP8DPP9FAPDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | NORTHWEST UNIVERSITY (CN) | 2022-06-14 | — | — | US | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| CN-108513574-A | N-sulfonylated pyrazolo [3,4-b ] pyridine-6-carboxamides and methods of use | 艾伯维公司 | 2018-09-07 | — | — | CN | disclosed |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | GALAPAGOS SASU (FR) | 2018-04-19 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| US-9890158-B2 | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2018-02-13 | — | — | US | disclosed |
| EP-3225627-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Northwest University (CN) | 2017-10-04 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| US-20090312310-A1 | Imidazothiazole derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| CN-101605798-A | Imidazothiazole derivative | DAIICHI SANKYO CO LTD (JP) | 2009-12-16 | — | — | CN | disclosed |
| EP-2103619-A1 | IMIDAZOTHIAZOLE DERIVATIVES | Daiichi Sankyo Company, Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| US-4550107-A | Condensed diazepinones, their compositions and methods of use as pharmaceuticals | DR. KARL THOMAE GMBH (DE) | 1985-10-29 | — | — | US | disclosed |
| EP-0156191-A2 | Condensed diazepinones, process for their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | DPP4 2699/4885DPP8 2973/4885DPP9 2264/4885 |
| US-20090312310-A1 | Imidazothiazole derivatives | TP53, MDM2, TP53BP1 | DPP4 2929/4885DPP8 3304/4885DPP9 3492/4885 |
| US-11358985-B2 | Tripeptide compound, preparation method therefor, and application thereof | VIP, PREP, ACE | DPP4 25/4885DPP8 14/4885DPP9 22/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | DPP4 818/4885DPP8 1042/4885DPP9 1188/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | DPP4 745/4885DPP8 1030/4885DPP9 1137/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | DPP4 818/4885DPP8 1042/4885DPP9 1188/4885 |
| US-20180105522-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | DPP4 745/4885DPP8 1030/4885DPP9 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.